We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioTrove Screens two Million Samples Using RapidFire™ Lead Discovery

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioTrove Screens two Million Samples Using RapidFire™ Lead Discovery"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

BioTrove, Inc. has announced the screening of two million individual samples using their RapidFire™ Lead Discovery System.

RapidFire™ is a mass spectrometry-based, high-throughput screening platform that is designed to facilitate label-free screening of challenging drug targets using native substrates.

BioTrove currently provides screening services and instrumentation to nine large pharmaceutical and biotechnology companies.

Four of these clients will present results of lead discovery campaigns at the upcoming Society for Biomolecular Sciences (SBS) conference (Seattle, WA, September 17-21), demonstrating RapidFire™ screening of previously intractable drug targets.

RapidFire™ Lead Discovery uses mass spectrometry to enable high throughput screening of functional biochemical assays via label-free analysis of native substrates.

The platform is designed to analyze individual assays at throughputs of four to eight seconds per sample-a dramatic increase in throughput over conventional liquid chromatography-mass spectrometry systems.

BioTrove offers access to the Lead Discovery System as a screening service that includes assay development, primary screening, and support of secondary screening and chemistry programs. Technology transfer is available for clients who prefer to own their systems.

"We feel that the addition of six new customers in the past year, along with the screening of our two millionth client sample, truly validates the ability of the RapidFire™ platform to unlock the potential of a wide range of challenging HTS targets," said Can (Jon) Oezbal, Ph.D., Director of the RapidFire™ program.

"The RapidFire™ system has now been used to identify lead compounds in a wide range of high-throughput screening projects, ranging from key metabolic disease, cardiovascular, and oncology targets to novel targets in the anti-infective and anti-fungal areas."

Presentations will be made at the upcoming SBS meeting by BioTrove's RapidFire™ clients from Bayer Pharmaceuticals, Pfizer Inc., Schering Plough Research Institute, and Sirtris Pharmaceuticals. BioTrove will also exhibit at SBS, at booth number 636.